Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diasorin SpACHIX:DIAM -1.71%78 EV-to-EBIT is 18.64 as of Jul. 14, 2026, which is 10% below its 10-year median of 20.63. GuruFocus rates CHIX:DIAM with a GF Score™ of 78/100 and a GF Value™ of €90.24 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 59.05% on this metric.
The historical rank and industry rank for Diasorin SpA's EV-to-EBIT or its related term are showing as below:
CHIX:DIAm'
s EV-to-EBIT Range Over the Past 10 Years
Min: 13.64 Med: 20.63 Max: 51.24
Current: 18.64
During the past 13 years, the highest EV-to-EBIT of Diasorin SpA was 51.24. The lowest was 13.64. And the median was 20.63.
CHIX:DIAm's EV-to-EBIT is ranked better than 59.05% of 105
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.66
vs CHIX:DIAm: 18.64
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Diasorin SpA's Enterprise Value for the quarter that ended in Dec. 2025 was €4,155 Mil.
Diasorin SpA's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €215 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA EV-to-EBIT Related Terms
Diasorin SpA EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIAM vs TMO, DHR, IDXX: EV-to-EBIT Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's EV-to-EBIT falls into.
Diasorin SpA's current Enterprise Value is €4,013 Mil.
Diasorin SpA's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €215 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA (CHIX:DIAM) has a EV-to-EBIT of 18.64 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Diasorin SpA and its competitors. This is 10% below median its historical median of 20.63. Over the past decade, Diasorin SpA's EV-to-EBIT has ranged from 13.64 to 51.24. According to the industry distribution chart, Diasorin SpA ranks #43 out of 105 companies in the Medical Diagnostics & Research industry, placing it in the top 41%.
Is Diasorin SpA's EV-to-EBIT too high?
Diasorin SpA's current EV-to-EBIT of 18.64 is 10% below median its 10-year median of 20.63. Over the past 10 years, this metric has ranged from a low of 13.64 to a high of 51.24. The Medical Diagnostics & Research industry median EV-to-EBIT is 22.66. Diasorin SpA's value of 18.64 is 17.7% below this industry median. Based on the distribution chart, Diasorin SpA ranks #43 out of 105 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #43 out of 105 companies for EV-to-EBIT. This puts Diasorin SpA in the upper half of its industry. The industry median EV-to-EBIT is 22.66. Diasorin SpA's value of 18.64 is 17.7% below this benchmark. Historically, Diasorin SpA's own EV-to-EBIT has ranged from 13.64 to 51.24 over the past decade. While the company's 10-year median is 20.63 vs. the industry median of 22.66, Diasorin SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.66, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diasorin SpA's current EV-to-EBIT of 18.64 is 17.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Diasorin SpA and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current EV-to-EBIT is 18.64, which is 10% below median its own 10-year median of 20.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (CHIX:DIAM) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.24, compared to a current price of €69.54 — trading 22.9% below its estimated fair value. The current EV-to-EBIT is 18.64, which is 10% below median its 10-year median of 20.63 and 17.7% below the Medical Diagnostics & Research industry median of 22.66. Diasorin SpA's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Diasorin SpA (CHIX:DIAM), the current EV-to-EBIT is 18.64 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (CHIX:DIAM) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €69.54 is trading 22.9% below its estimated GF Value™ of €90.24.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for CHIX:DIAM:
EV-to-EBIT: 18.64 (10% below median its 10-year median of 20.63)
GF Value™: €90.24 vs. price of €69.54 (22.9% below fair value)
Industry Position: 17.7% below the Medical Diagnostics & Research median (#43 of 105)
No single metric tells the full story. See the CHIX:DIAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
78GF Score
Get the complete analysis for CHIX:DIAM
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIAM has been successfully added to your 
